Anti-transferrin receptor antibodies

Antibodies targeting the transferrin receptor (TfRl) with specific CDR sequences and VH domains address the need for targeted cellular delivery by achieving high affinity and minimal transferrin interference, enabling effective cellular uptake and transcytosis.

WO2026236399A1PCT designated stage Publication Date: 2026-11-12LYCIA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026957
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current technologies lack effective antibodies or antigen-binding fragments that specifically target the transferrin receptor (TfRl) for applications such as introducing agents into cells or crossing the blood-brain barrier, while maintaining minimal interference with transferrin binding.

Method used

Development of antibodies and antigen-binding fragments that bind to human TfRl, comprising specific CDR sequences and a VH domain, with the ability to target the apical domain and exhibit high affinity without inhibiting transferrin binding.

Benefits of technology

The antibodies achieve high binding affinity to TfRl with KD values of 6.97*10^-9 M or less, allowing targeted delivery across the blood-brain barrier without significantly interfering with transferrin binding, thus providing a means for effective cellular uptake and transcytosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000009_0001_TABLE
    Figure IMGF000009_0001_TABLE
  • Figure IMGF000012_0001_TABLE
    Figure IMGF000012_0001_TABLE
  • Figure IMGF000014_0001_TABLE
    Figure IMGF000014_0001_TABLE
Patent Text Reader

Abstract

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind the transferrin receptor (TfR1).
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket Number: 92VF-409083-WOANTI- TRANSFERRIN RECEPTOR ANTIBODIESCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63 / 801,732, filed May 7, 2025, which is hereby incorporated by reference in its entirety.BACKGROUND

[0002] The transferrin receptor (CD71, TfR, or TfRl) is a transferrin transporter protein required for the transportation of iron into the cell and is regulated in response to intracellular iron concentration. Transferrin receptors are expressed on endothelium, including the endothelium of the blood-brain barrier, and are expressed at high levels on cancer cells and inflammatory cells. Transferrin receptors are one of the receptors that mediate the transcytosis of related ligands across the blood-brain barrier. Transferrin receptors may be desirable targets for introducing an agent into a cell for endocytosis into the cell or transcytosis through the cell.SUMMARY

[0003] This disclosure provides for antibodies and antigen-binding fragments thereof that bind the transferrin receptor.

[0004] According to one aspect, an antibody or antigen-binding fragment thereof is provided. The antibody or antigen-binding fragment thereof binds to human TfRl and comprises: a CDRH1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110; a CDRH2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126; and a CDRH3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 127, 128, 129, 130, and 131.

[0005] In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50. In some embodiments, the antibody or antigenbinding fragment thereof comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3-18, 20-24, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3-18, and 20-24. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VHAttomey Docket Number: 92VF-409083-WOdomain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3-18, and 20-24.

[0006] In some embodiments, the antibody or antigen-binding fragment thereof comprises the CDRH1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 101, 105, and 106; the CDRH2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 114, 115, and 116; and the CDRH3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 127, 128, 129, 130, and 131.

[0007] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (a) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 101; the CDRH2 comprising an amino acid sequence of SEQ ID NO: 116; and the CDRH3 comprising an amino acid sequence of SEQ ID NO: 127; (b) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 105; the CDRH2 comprising an amino acid sequence of SEQ ID NO: 114; and the CDRH3 comprising an amino acid sequence of SEQ ID NO: 127; (c) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 106; the CDRH2 comprising an amino acid sequence of SEQ ID NO: 115; and the CDRH3 comprising an amino acid sequence of SEQ ID NO: 127; or (d) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 106; the CDRH2 comprising an amino acid sequence of SEQ ID NO: 114; and the CDRH3 comprising an amino acid sequence of SEQ ID NO: 127.

[0008] In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50.

[0009] In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region. The Fc region may be derived from human IgGl. The Fc region may comprise the amino acid sequence of SEQ ID NO: 132.

[0010] In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 51-100. In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 64, 65, 66, 87, 98, and 100. In some embodiments, the antibody or antigen-binding fragment thereof is a heavy chain-only antibody (HCAb) or a fragment thereof.

[0011] According to one aspect, a heavy chain-only antibody (HCAb) or antigen-binding fragment thereof is provided. The heavy chain-only antibody binds to human TfRl and comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50.

[0012] In some embodiments, the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50. In some embodiments, the heavy chain-Attorney Docket Number: 92VF-409083-WOonly antibody (HCAb) or antigen-binding fragment thereof comprises an Fc region comprising the amino acid sequence of SEQ ID NO: 132.

[0013] In some embodiments, the antibody or antigen-binding fragment thereof of any preceding paragraphs binds to the apical domain of human TfRl. In some embodiments, the antibody or antigenbinding fragment thereof of any preceding paragraphs binds to human TfRl with KD value of 6.97* 10'9M or less, 1* IO10M or less, 1* IO11M or less, or 1* IO12M or less. In some embodiments, the antibody or antigen-binding fragment thereof of any preceding paragraphs does not substantially inhibit binding of transferrin to TfRl. In some embodiments, the antibody or antigen-binding fragment thereof of any preceding paragraphs inhibits binding of transferrin to TfRl by less than 20%.

[0014] According to one aspect, provided is a composition comprising the antibody or antigenbinding fragment thereof of any preceding paragraphs.

[0015] According to one aspect, provided is a polynucleotide encoding one of the polypeptide chains of the antibody or antigen-binding fragment thereof of any preceding paragraphs.

[0016] According to one aspect, provided is an isolated cell comprising one or more polynucleotide encoding the antibody or fragment thereof of any preceding paragraphs.DETAILED DESCRIPTIONDefinitions

[0017] It is to be noted that the term “a” or “an” entity refers to one or more of that entity; for example, “an antibody,” is understood to represent one or more antibodies. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.

[0018] As used herein, the term “polypeptide” is intended to encompass a singular “polypeptide” as well as plural “polypeptides,” and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term “polypeptide” refers to any chain or chains of two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, “protein,” “amino acid chain,” or any other term used to refer to a chain or chains of two or more amino acids, are included within the definition of “polypeptide,” and the term “polypeptide” may be used instead of, or interchangeably with any of these terms. The term “polypeptide” is also intended to refer to the products of post-expression modifications of the polypeptide, including without limitation glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or modification by non- naturally occurring amino acids. A polypeptide may be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It may be generated in any manner, including by chemical synthesis.Attorney Docket Number: 92VF-409083-WO

[0019] As used herein, the term “recombinant” as it pertains to polypeptides or polynucleotides intends a form of the polypeptide or polynucleotide that does not exist naturally, a non-limiting example of which can be created by combining polynucleotides or polypeptides that would not normally occur together.

[0020] The term “isolated” as used herein refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The term “isolated” is also used herein to refer to cells or polypeptides which are isolated from other cellular proteins or tissues. Isolated polypeptides is meant to encompass both purified and recombinant polypeptides.

[0021] “Homology” or “identity” or “similarity” refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. An “unrelated” or “non-homologous” sequence shares less than 40% identity, though preferably less than 25% identity, with one of the sequences of the present disclosure.

[0022] A polypeptide or polypeptide region has a certain percentage (for example, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 98 % or 99 %) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in Ausubel et al. eds. (2007) Current Protocols in Molecular Biology. Preferably, default parameters are used for alignment. One alignment program is BLAST, using default parameters. In particular, programs are BLASTN and BLASTP, using the following default parameters: Genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + SwissProtein + SPupdate + PIR. Biologically equivalent polynucleotides are those having the above-noted specified percent homology and encoding a polypeptide having the same or similar biological activity.

[0023] The term “an equivalent nucleic acid or polynucleotide” refers to a nucleic acid having a nucleotide sequence having a certain degree of homology, or sequence identity, with the nucleotide sequence of the nucleic acid or complement thereof. A homolog of a double stranded nucleic acid is intended to include nucleic acids having a nucleotide sequence which has a certain degree of homology with or with the complement thereof. In one aspect, homologs of nucleic acids are capable of hybridizing to the nucleic acid or complement thereof. Likewise, “an equivalent polypeptide” refersAttorney Docket Number: 92VF-409083-WOto a polypeptide having a certain degree of homology, or sequence identity, with the amino acid sequence of a reference polypeptide. In some aspects, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%. In some aspects, the equivalent polypeptide or polynucleotide has one, two, three, four or five additions, deletions, substitutions and their combinations thereof as compared to the reference polypeptide or polynucleotide. In some aspects, the equivalent sequence retains the activity (e.g., epitope-binding) or structure (e.g., salt-bridge) of the reference sequence.

[0024] Hybridization reactions can be performed under conditions of different “stringency”. In general, a low stringency hybridization reaction is carried out at about 40°C in about 10 x SSC or a solution of equivalent ionic strength / temperature. A moderate stringency hybridization is typically performed at about 50°C in about 6 x SSC, and a high stringency hybridization reaction is generally performed at about 60°C in about 1 x SSC. Hybridization reactions can also be performed under “physiological conditions” which is well known to one of skill in the art. A non-limiting example of a physiological condition is the temperature, ionic strength, pH and concentration of Mg2+ normally found in a cell.

[0025] A polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching. The term “polymorphism” refers to the coexistence of more than one form of a gene or portion thereof. A portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a “polymorphic region of a gene”. A polymorphic region can be a single nucleotide, the identity of which differs in different alleles.

[0026] The terms “polynucleotide” and “oligonucleotide” are used interchangeably and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides can have any three dimensional structure and may perform any function, known or unknown. The following are non limiting examples of polynucleotides: a gene or gene fragment (for example, a probe, primer, EST or SAGE tag), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polynucleotide. The sequence of nucleotides can be interrupted by non nucleotide components. A polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double and single stranded molecules. Unless otherwise specified or required, anyAttorney Docket Number: 92VF-409083-WOembodiment of this disclosure that is a polynucleotide encompasses both the double stranded form and each of two complementary single stranded forms known or predicted to make up the double stranded form.

[0027] The term “encode” as it is applied to polynucleotides refers to a polynucleotide which is said to “encode” a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and / or translated to produce the mRNA for the polypeptide and / or a fragment thereof. The antisense strand is the complement of such a nucleic acid, and the encoding sequence can be deduced therefrom.

[0028] As used herein, an “antibody” or “antigen-binding polypeptide” refers to a polypeptide or a polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a whole antibody and any antibody fragment (or antigen-binding fragment) or a single chain thereof. Thus, the term “antibody” includes any protein or peptide-containing molecule that comprises at least a portion of an immunoglobulin molecule having biological activity of binding to the antigen. Examples of such include, but are not limited to a complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework (FR) region, or any portion thereof, or at least one portion of a binding protein.

[0029] The terms “antibody fragment” or “antigen-binding fragment”, as used herein, is a portion of an antibody such as VH, Fab, F(ab’)2, F(ab)2, Fab’, Fv, scFv, scFv-Fc, scFv-CH, scFab, scFv-zipper, and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. The term “antibody fragment” also includes aptamers, spiegelmers, and diabodies. The term “antibody fragment” also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.

[0030] A “single-chain variable fragment” or “scFv” refers to a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of immunoglobulins. In some aspects, the regions are connected with a short linker peptide of ten to about 25 amino acids. The linker can be rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of the linker. ScFv molecules are known in the art and are described, e.g., in US patent 5,892,019.

[0031] The term antibody encompasses various broad classes of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (y, p, a, 5, a) with some subclasses among them (e.g., yl-y4). It is the nature of this chain that determines the “class” of the antibody as IgG, IgM, IgA, IgD, or IgE, respectively.

[0032] The immunoglobulin subclasses (isotypes) e.g., IgGl, IgG2, IgG3, IgG4, IgG5, etc. are well characterized and are known to confer functional specialization. Modified versions of each of theseAttorney Docket Number: 92VF-409083-WOclasses and isotypes are readily discernable to the skilled artisan in view of the instant disclosure and, accordingly, are within the scope of the instant disclosure. All immunoglobulin classes are clearly within the scope of the present disclosure, the following discussion will generally be directed to the IgG class of immunoglobulin molecules. With regard to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides of molecular weight approximately 23,000 Daltons, and two identical heavy chain polypeptides of molecular weight 53,000-70,000. The four chains are typically joined by disulfide bonds in a “Y” configuration wherein the light chains bracket the heavy chains starting at the mouth of the “Y” and continuing through the variable region.

[0033] Antibodies, antigen-binding polypeptides, variants, or derivatives thereof of the disclosure include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, primatized, or chimeric antibodies, single chain antibodies, epitope-binding fragments, e.g., Fab, Fab’ and F(ab’)2, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv), fragments comprising either a VK or VH domain, fragments produced by a Fab expression library, and anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to the antibodies disclosed herein). Immunoglobulin or antibody molecules of the disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.

[0034] Light chains are classified as either kappa or lambda (K, X). Each heavy chain class may be bound with either a kappa or lambda light chain. In general, the light and heavy chains are covalently bonded to each other, and the “tail” portions of the two heavy chains are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells or genetically engineered host cells. In the heavy chain, the amino acid sequences run from an N-terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each chain.

[0035] Both the light and heavy chains are divided into regions of structural and functional homology. The terms “constant” and “variable” are used functionally. In this regard, it will be appreciated that the variable domains of both the light (VK or VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CK or CL) and the heavy chain (CHI, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. By convention the numbering of the constant region domains increases as they become more distal from the antigen-binding site or amino- terminus of the antibody. The N-terminal portion is a variable region and at the C-terminal portion is a constant region; the CH3 and CK domains actually comprise the carboxy-terminus of the heavy and light chain, respectively.

[0036] As indicated above, the variable region allows the antibody to selectively recognize and specifically bind epitopes on antigens. That is, the VK domain and VH domain, or subset of the complementarity determining regions (CDRs), of an antibody combine to form the variable regionAttorney Docket Number: 92VF-409083-WOthat defines a three-dimensional antigen-binding site. This quaternary antibody structure forms the antigen-binding site present at the end of each arm of the Y. More specifically, the antigen-binding site is defined by three CDRs on each of the VH and VK chains (i.e. CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3). In some instances, e.g., certain immunoglobulin molecules derived from camelid species or engineered based on camelid immunoglobulins, a complete immunoglobulin molecule may consist of heavy chains only, with no light chains. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993).

[0037] As used herein, the term “chimeric antibody” will be held to mean any antibody wherein the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be intact, partial or modified in accordance with the instant disclosure) is obtained from a second species. In certain embodiments the target binding region or site will be from a non-human source (e.g. mouse or primate) and the constant region is human.

[0038] Antibodies disclosed herein can be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In some embodiments, the variable region may be condricthoid in origin (e.g., from sharks).

[0039] The terms “heavy chain-only antibody,” “heavy-chain antibody” and “HCAb” are used interchangeably, and refer, in the broadest sense, to antibodies lacking the light chain of a conventional antibody. Since HCAbs lack a light chain and thus a VL domain, the antigen is recognized by one single domain, i.e., the variable domain of the heavy chain of a heavy-chain antibody (VH). The term specifically includes, without limitation, antibodies comprising the VH antigen-binding domain and the CH2 and CH3 constant domains, in the absence of the CHI domain; functional (antigen-binding) variants of such antibodies, soluble VH variants, Ig-NAR comprising a homodimer of one variable domain (V-NAR) and five C-like constant domains (C-NAR) and functional fragments thereof; and soluble single domain antibodies (sdAbs). In one embodiment, the heavy chain-only antibody includes the variable region antigen-binding domain composed of framework 1, CDR1, framework 2, CDR2, framework 3, CDR3, and framework 4. In one embodiment, the heavy chain-only antibody includes an antigen-binding domain, at least part of a hinge region and CH2 and CH3 domains. In another embodiment, the heavy chain-only antibody includes an antigen-binding domain, at least part of a hinge region and a CH2 domain. In a further embodiment, the heavy chain-only antibody includes an antigen-binding domain, at least part of a hinge region and a CH3 domain. Heavy chain-only antibodies in which the CH2 and / or CH3 domain is truncated are also included herein. In a further embodiment the heavy chain is composed of an antigen binding domain, and at least one CH (CHI, CH2, CH3, or CH4) domain but no hinge region. The heavy chain-only antibody can be in the form of a dimer, in which two heavy chains are disulfide bonded other otherwise, covalently or non-covalently attached with each other. The heavy chain-only antibody may belong to the IgG subclass, but antibodies belonging to other subclasses, such as IgM,Attorney Docket Number: 92VF-409083-WOIgA, IgD and IgE subclass, are also included herein. In a particular embodiment, the heavy chain antibody is of the IgGl, IgG2, IgG3, or IgG4 subtype, in particular IgGl subtype.

[0040] In the case where there are two or more definitions of a term which is used and / or accepted within the art, the definition of the term as used herein is intended to include all such meanings unless explicitly stated to the contrary. A specific example is the use of the term “complementarity determining region” (“CDR”) to describe the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. This particular region has been described by Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and by Chothia et al., J. Mol. Biol. 196:901-917 (1987), which are incorporated herein by reference in their entireties. The CDR definitions according to Kabat and Chothia include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth in Table 1 below as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.Table 1Kabat ChothiaCDR-H1 31-35 26-32CDR-H2 50-65 52-58CDR-H3 95-102 95-102

[0041] Kabat et al. also defined a numbering system for variable domain sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of “Kabat numbering” to any variable domain sequence, without reliance on any experimental data beyond the sequence itself. As used herein, “Kabat numbering” refers to the numbering system set forth by Kabat et al., U.S. Dept, of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983).

[0042] In addition to Table 1 above, the Kabat number system describes the CDR regions as follows: CDR-H1 begins at approximately amino acid 31 (i.e., approximately 9 residues after the first cysteine residue), includes approximately 5-7 amino acids, and ends at the next tryptophan residue. CDR-H2 begins at the fifteenth residue after the end of CDR-H1, includes approximately 16-19 amino acids, and ends at the next arginine or lysine residue. CDR-H3 begins at approximately the thirty third amino acid residue after the end of CDR-H2; includes 3-25 amino acids; and ends at the sequence W-G-X-G, where X is any amino acid.Attorney Docket Number: 92VF-409083-WO

[0043] Throughout this application, amino acid numbers are according to Kabat numbering system, unless specified otherwise.

[0044] As used herein, the term “heavy chain constant region” includes amino acid sequences derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region comprises at least one of: a CHI domain, a hinge (e.g. , upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, an antigen-binding polypeptide for use in the disclosure may comprise a polypeptide chain comprising a CHI domain; a polypeptide chain comprising a CHI domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain comprising a CHI domain and a CH3 domain; a polypeptide chain comprising a CHI domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain comprising a CHI domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, a polypeptide of the disclosure comprises a polypeptide chain comprising a CH3 domain. Further, an antibody for use in the disclosure may lack at least a portion of a CH2 domain (e.g. , all or part of a CH2 domain). As set forth above, it will be understood by one of ordinary skill in the art that the heavy chain constant region may be modified such that they vary in amino acid sequence from the naturally occurring immunoglobulin molecule.

[0045] The heavy chain constant region of an antibody disclosed herein may be derived from different immunoglobulin molecules. For example, a heavy chain constant region of a polypeptide may comprise a CHI domain derived from an IgGi molecule and a hinge region derived from an IgGs molecule. In another example, a heavy chain constant region can comprise a hinge region derived, in part, from an IgGi molecule and, in part, from an IgGs molecule. In another example, a heavy chain portion can comprise a chimeric hinge derived, in part, from an IgGi molecule and, in part, from an IgG4molecule. In some embodiments, a heavy chain constant region may comprise a CH2 domain and a CH3 domain derived from an IgGi molecule.

[0046] As used herein the term “CH2 domain” includes the portion of a heavy chain molecule that extends, e.g., from about residue 244 to residue 360 of an antibody using conventional numbering schemes (residues 244 to 360, Kabat numbering system; and residues 231-340, EU numbering system; see Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983). The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It is also well documented that the CH3 domain extends from the CH2 domain to the C-terminal of the IgG molecule and comprises approximately 108 residues.

[0047] As used herein, the term “hinge region” includes the portion of a heavy chain molecule that joins the antigen binding region (i.e. VH domain) to the CH2 domain. This hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regionsAttorney Docket Number: 92VF-409083-WOto move independently. Hinge regions can be subdivided into three distinct domains: upper, middle, and lower hinge domains (Roux et al., J. Immunol 161:4083 (1998)).

[0048] By “specifically binds” or “has specificity to,” it is generally meant that an antibody binds to an epitope via its antigen-binding domain, and that the binding entails some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is said to “specifically bind” to an epitope when it binds to that epitope, via its antigen-binding domain more readily than it would bind to a random, unrelated epitope. The term “specificity” is used herein to qualify the relative affinity by which a certain antibody binds to a certain epitope. For example, antibody “A” may be deemed to have a higher specificity for a given epitope than antibody “B,” or antibody “A” may be said to bind to epitope “C” with a higher specificity than it has for related epitope “D.”

[0049] As used herein, the terms “treat” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of cancer. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (z. e. , not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0050] By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include humans, domestic animals, farm animals, and zoo, sport, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and so on.

[0051] As used herein, phrases such as “to a patient in need of treatment” or “a subject in need of treatment” includes subjects, such as mammalian subjects, that would benefit from administration of an antibody or composition of the present disclosure used, e.g., for detection, for a diagnostic procedure and / or for treatment.Anti-TfRl Antibodies and Antibody Fragments

[0052] The present invention provides anti-TfRl antibodies and antibody fragments thereof. In some embodiments, the antibody or antibody fragment is a heavy-chain antibody or an HCAb, or a fragment thereof. Such antibodies or antibody fragments bind to one or more amino acid residues selected from the human TfRl protein. The antibodies or antibody fragments may have binding affinity to human TfRl protein, in nanomolar KD value. For example, the antibodies or antibody fragments may have KD value of less than about MO'7M, less than about 1 x 10'8M, less than aboutAttorney Docket Number: 92VF-409083-WO1 x 10"9M, less than about IxlO-10M, less than about lx 10'11M, or less than about IxlO-12M. In some embodiments, the antibodies or antibody fragments may have KD value of less than about 6.92 x 10'9M.

[0053] In some embodiments, the antibody or antibody fragment binds the apical domain of TfRl, such that it does not compete with transferrin for binding to TfRl . For example, the antibody or antibody fragment does not inhibit binding of transferrin to TfRl, showing blocking rate (%) of less than about 30%, about 20%, about 10%, or about 5%, as shown in the following examples.

[0054] The human TfRl protein, as known in the art, includes 760 amino acid residues, as shown in SEQ ID NO: 133 in Table 2 below.Table 2Name Amino Acid Sequence of HuTfRl (SEQ ID NO: 133)Human TfRl MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKP KRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGEDFPAprotein ARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVENQFREFK LSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHAN FGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAEL SFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNMEGDCP SDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVWGAQRDAWG PGAAKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYLS SLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASK VEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARAA AEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGDF FRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF Sequences

[0055] In accordance with one embodiment of the present disclosure, provided is an isolated antibody or fragment thereof that bind human TfRl . In some embodiments, the antibody or antibody fragments include a heavy chain variable region CDRs (CDRH1, CDRH2, CDRH3).

[0056] In some embodiments, the CDRH1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110, shown in Table 3. In some embodiments, the CDRH1 comprises a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110 having one, two or three substitution, deletion or insertion as compared to SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, or 110, respectively.

[0057] In some embodiments, the CDRH1 has an amino acid sequence selected from the group consisting ofSEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110, shown in Table 3. In some embodiments, the CDRH1 has a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110 having one, two or three substitution, deletion or insertion as compared to SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, or 110, respectively.Attorney Docket Number: 92VF-409083-WO

[0058] In some embodiments, the CDRH2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126, shown in Table 3. In some embodiments, the CDRH2 comprises a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126 having one, two or three substitution, deletion or insertion as compared to SEQ ID NO: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, or 126, respectively.

[0059] In some embodiments, the CDRH2 has an amino acid sequence selected from the group consisting ofSEQ ID NO: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126, shown in Table 3. In some embodiments, the CDRH2 has a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126 having one, two or three substitution, deletion or insertion as compared to SEQ ID NO: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, or 126, respectively.

[0060] In some embodiments, the CDRH3 comprises an amino acid sequence selected from the group consisting ofSEQ ID NO: 127, 128, 129, 130, and 131, shown in Table 3. In some embodiments, the CDRH3 comprises a variant of an amino acid sequence selected from the group consisting ofSEQ ID NO: 127, 128, 129, 130, and 131 having one, two or three substitution, deletion or insertion as compared to SEQ ID NO: 127, 128, 129, 130, or 131, respectively.

[0061] In some embodiments, the CDRH3 has an amino acid sequence selected from the group consisting ofSEQ ID NO: 127, 128, 129, 130, and 131, shown in Table 3. In some embodiments, the CDRH3 has a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: 127, 128, 129, 130, and 131 having one, two or three substitution, deletion or insertion as compared to SEQ ID NO: 127, 128, 129, 130, or 131, respectively.

[0062] In some embodiments, CDRH1 comprises an amino acid sequence selected from the group consisting ofSEQ ID NO: 101, 105, and 106. In some embodiments, CDRH1 comprises SEQ ID NO: 101. In some embodiments, CDRH1 comprises SEQ ID NO: 105. In some embodiments, CDRH1 comprises SEQ ID NO: 106.

[0063] In some embodiments, CDRH2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 114, 115, and 116. In some embodiments, CDRH2 comprises SEQ ID NO: 114. In some embodiments, CDRH2 comprises SEQ ID NO: 115. In some embodiments, CDRH2 comprises SEQ ID NO: 116.

[0064] In some embodiments, CDRH3 comprises SEQ ID NO: 127. In some embodiments, CDRH3 comprises SEQ ID NO: 128. In some embodiments, CDRH3 comprises SEQ ID NO: 129. In some embodiments, CDRH3 comprises SEQ ID NO: 130. In some embodiments, CDRH3 comprises SEQ ID NO: 131.Attorney Docket Number: 92VF-409083-WO

[0065] In some embodiments, CDRH1 has an amino acid sequence selected from the group consisting of SEQ ID NO: 101, 105, and 106. In some embodiments, CDRH1 has the amino acid sequence of SEQ ID NO: 101. In some embodiments, CDRH1 has the amino acid sequence of SEQ ID NO: 105. In some embodiments, CDRH1 has the amino acid sequence of SEQ ID NO: 106.

[0066] In some embodiments, CDRH2 has an amino acid sequence selected from the group consisting of SEQ ID NO: 114, 115, and 116. In some embodiments, CDRH2 has the amino acid sequence of SEQ ID NO: 114. In some embodiments, CDRH2 has the amino acid sequence of SEQ ID NO: 115. In some embodiments, CDRH2 has the amino acid sequence of SEQ ID NO: 116.

[0067] In some embodiments, CDRH3 has the amino acid sequence of SEQ ID NO: 127. In some embodiments, CDRH3 has the amino acid sequence of SEQ ID NO: 128. In some embodiments, CDRH3 has SEQ ID NO: 129. In some embodiments, CDRH3 has the amino acid sequence of SEQ ID NO: 130. In some embodiments, CDRH3 has the amino acid sequence of SEQ ID NO: 131.

[0068] In some embodiments, CDRH1, CDRH2, and CDRH3 comprise, respectively, the amino acid sequence of SEQ ID NO: 101, 116, and 127. In some embodiments, CDRH1, CDRH2, and CDRH3 comprise, respectively, the amino acid sequence of SEQ ID NO: 105, 114, and 127. In some embodiments, CDRH1, CDRH2, and CDRH3 comprise, respectively, the amino acid sequence of SEQ ID NO: 106, 115, and 127. In some embodiments, CDRH1, CDRH2, and CDRH3 comprise, respectively, the amino acid sequence of SEQ ID NO: 106, 114, and 127.

[0069] In some embodiments, CDRH1, CDRH2, and CDRH3 have, respectively, the amino acid sequence of SEQ ID NO: 101, 116, and 127. In some embodiments, CDRH1, CDRH2, and CDRH3 have, respectively, the amino acid sequence of SEQ ID NO: 105, 114, and 127. In some embodiments, CDRH1, CDRH2, and CDRH3 have, respectively, the amino acid sequence of SEQ ID NO: 106, 115, and 127. In some embodiments, CDRH1, CDRH2, and CDRH3 have, respectively, the amino acid sequence of SEQ ID NO: 106, 114, and 127.Table 3Sequence SEQ ID NO:CDRH1 GFIFSDYYMS 101GFNFSDYYMS 102GFTFRDYYMS 103GFTFSDHYMS 104GFTFSDNYMS 105GFTFSDYYMS 106GFTFGSYAMT 107GFTFSSYAMS 108GFTFSSYAMT 109GFTLSSYAMS 110CDRH2 YISGNGDTINYADSVKG 111YISGNGDTIQYADSVKG 112 YISGSGDTIHYADSVKG 113 YISGSGDTINYADSVKG 114YISGSGDTIQYADSVKG 115Attorney Docket Number: 92VF-409083-WOYISGSGDTIQYADSVQG 116 YISNNGSTIQYADSVKG 117 YISSNGSTIQYADSVKG 118 YISSSGDTINYADSVKG 119 AISGGGDNTYYADSVKG 120 AISGSGGSTYYADSVKG 121 SISGGGDSTYYADSVKG 122 SISGSGDSTYYADSVKG 123 SISGSGGSTYYADSVKG 124 TISGSGDNTYYADSVKG 125 TISGSGGSTYYADSVKG 126CDRH3 GYNSNYLDWFDP 127GYYSNYLDWFDP 128APYYDILTGYSPVHY 129DPYYDILSGYSAAAY 130DPYYDILTGYSAAVY 131

[0070] In some embodiments, the isolated antibody or antibody fragments include a VH domain including a sequence selected of the group consisting of SEQ ID NOS: 1-50, shown in Table 4, or their respective biological equivalents. A biological equivalent of a VH is a sequence that includes the designated amino acids while having an overall 80%, 85%, 90%, 95%, 98% or 99% sequence identity. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 80% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 80% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 85% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 90% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 95% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 98% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having sequence identity of 99% or greater to a sequence selected of the group consisting of SEQ ID NOS: 1-50. In some embodiments, the isolated antibody or antibody fragments include a VH domain having a sequence selected of the group consisting of SEQ ID NOS: 1-50.

[0071] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising a sequence selected from the group consisting of SEQ ID NO: 14, 15, 16, 37, 48, and 50. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chainAttorney Docket Number: 92VF-409083-WOcomprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 48. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 50.

[0072] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising a sequence selected from the group consisting of SEQ ID NO: 14, 15, 16, 37, 48, and 50. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising SEQ ID NO: 14. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising SEQ ID NO: 15. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising SEQ ID NO: 16. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising SEQ ID NO: 37. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising SEQ ID NO: 48. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a VH domain comprising SEQ ID NO: 50.Table 4SEQ ID Anti-TfRl HCAb VH domainsNO:1 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGNGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS2 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS3 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS4 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGGSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS5 EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWVSSISGGGDSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGKLVTVSS6 EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGDNTYYADS VKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS7 QVQLLESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWVSSISGSGDSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGNLVTVSS8 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS9 QVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSNGSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSSAtorney Docket Number: 92VF-409083-WOQVQLVESGGGLVQPGGSLRLSCAASGFNFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS QVQLVESGGGLVKPGGSLRLSCEASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS QVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGDNTYYADS VKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS QVQLVESGGGLVQPGGSLRLSCTASGFTLSSYAMSWVRQVPGKGLEWVSAISGGGDNTYYADS VKGRFTISRDTSKNTLYLQMNSLSAEDTAVYYCEKAPYYDILTGYSPVHYWGQGALVTVSS QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLVESGGGLVKPGGSLRLSCAASGFIFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLVESGGDLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWISYISSSGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGNLVTVSS QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSNGSTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS QVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGDNTYYADS VKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS QVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWVSSISGGGDSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGKLVTVSS EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGGSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS EVQLVESGGGLVKPGGSLRLSCAASGFTFRDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGDNTYYADS VKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWVSSISGSGGSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGNLVTVSS QVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWVSSISGSGGSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGNLVTVSS EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGDNTYYADS VKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSSAttorney Docket Number: 92VF-409083-WO32 EVQLLESGGGLVQPGGSLRLSCTASGFTLSSYAMSWVRQVPGKGLEWVSAISGGGDNTYYADS VKGRFTISRDTSKNTLYLQMNSLSAEDTAVYYCEKAPYYDILTGYSPVHYWGQGALVTVSS33 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS34 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGGSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILSGYSAAAYWGQGNLVTVSS35 EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS36 QVQLLESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWVSSISGGGDSTYYADS VKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCEKDPYYDILTGYSAAVYWGQGKLVTVSS37 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS38 QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS39 QVQLVESGGGLVQPGGSLRLSCTASGFTLSSYAMSWVRQVPGKGLEWVSAISGGGDNTYYADS VKGRFTISRDTSKNTLFLQMNSLSAEDTAVYYCEKAPYYDILTGYSPVHYWGQGALVTVSS40 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVRGYYSNYLDWFDPWGQGTLVTVSS41 EVQLVESGGGWQPGRSLRLSCAASGFTLSSYAMSWVRQVPGKGLEWVSAISGGGDNTYYADS VKGRFTISRDTSKNTLYLQMNSLSAEDTAVYYCEKAPYYDILTGYSPVHYWGQGALVTVSS42 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDHYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVRGYYSNYLDWFDPWGQGTLVTVSS43 QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTIHYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVRGYYSNYLDWFDPWGQGTLVTVSS44 QVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWVRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS45 EVQLVESGGGLVKPGGSLRLSCAASGFNFSDYYMSWIRQAPGKGLEWVSYISGSGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS46 QVQLLESGGGFVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISNNGSTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS47 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGNGDTIQYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVRGYYSNYLDWFDPWGQGTLVTVSS48 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTIQYADS VKGRFTISRDNGKNSMYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS49 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGSGDTINYADS VKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS50 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWVSYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLRGYNSNYLDWFDPWGQGTLVTVSS

[0073] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises an Fc domain. The Fc domain may be connected to the VH domain, or the antibody-binding domain. In some embodiments, the Fc domain is an IgGl Fc domain. In some embodiments, the Fc domain is a human IgGl Fc domain. In some embodiments, the Fc domain is a mouse IgGl Fc domain. In some embodiments, the Fc domain is a rat IgGl Fc domain. In some embodiments, the Fc domain is a rhesus macaque IgGl Fc domain. In some embodiments, the Fc domain is a cynomolgus macaqueAttorney Docket Number: 92VF-409083-WOIgGl Fc domain. In some embodiments, the Fc domain includes a portion of a human IgGl Fc domain. For example, the Fc domain includes CH2 and CH3 regions of the human IgGl. In some embodiments, the Fc domain is a native Fc domain. In some embodiments, the Fc domain is a nonnative Fc domain. In some embodiments, the non-native Fc domain comprises a mutation that increases its affinity for FcRn in acidic (pH 4.5 - 6.5) conditions. In some embodiments, the nonnative Fc domain comprises the M252Y / S254T / T256E mutation. In some embodiments, the nonnative Fc domain comprises the M252Y / S254T / T256E / H433K / N434F mutation. In some embodiments, the non-native Fc domain comprises the (M428L / N434S), (T307A / E380A / N434A), (T250Q / M428L) or V308P mutation. In some embodiments, the non-native Fc domain comprises a mutation that modulates effector function, which can reduce Fc(gamma) receptor binding and complement fixation. In some embodiments, the non-native Fc domain comprises the N297A, N297G or N297Q mutation. In some embodiments, the non-native Fc domain comprises the L234A / L235A or L234A / L235A / P329G mutation.

[0074] In some embodiments, the Fc domain includes an amino acid sequence of SEQ ID NO: 132 as shown in Table 5, or its biological equivalent. A biological equivalent of the Fc domain sequence is a sequence that includes the designated amino acids while having an overall 80%, 85%, 90%, 95%, 98% or 99% sequence identity with SEQ ID NO: 132.Table 5SEQ ID NO: human IgGl-Fc Domain Sequence132 GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0075] Referring to SEQ ID NO: 132, it will be understood to people with ordinary skill in the art that the leading GGGGS sequence (also referred to as G4S) is a flexible linker. In other embodiments, other linkers in place of this GGGGS linker may be used, including (G4S)n, where n is 1-20, preferably when n is 1-10 and most preferred when n is 1-5. Referring again to SEQ ID NO: 132, it will be understood to people with ordinary skill in the art that that a rigid or structured linker can be utilized in place of a flexible (G4S)nlinker. In other embodiments, a helical linker comprising (EAAAK)n, where n>l is utilized as the leading sequence. In other embodiments, a rigid linker comprising (XP)n, where n is 1-30 and X designating any amino acid, preferably Ala, Lys or Glu, is utilized as the leading sequence.

[0076] In some embodiments, the isolated antibody or antigen-binding fragment thereof includes a heavy chain including any of the VH domain described herein and any of the Fc domain described herein. For example, the sequence of the isolated antibody or antigen-binding fragment thereof includes a heavy chain including a VH domain having a sequence selected from the group consisting of SEQ ID NOS: 1-50, and an Fc domain having a sequence of SEQ ID NO: 132.Attorney Docket Number: 92VF-409083-WO

[0077] The amino acid sequence for the heavy chain of the isolated antibody or antigen-binding fragment (i.e., HCAb) is shown in Table 6. In some embodiments, the isolated antibody or antigenbinding fragment thereof includes a heavy chain including a sequence selected from the group consisting of SEQ ID NO: 51 to 100. In some embodiments, the isolated antibody or antigen-binding fragment thereof includes a heavy chain including a sequence having a sequence identity of at least about 80%, about 85%, about 90%, about 95%, about 98%, or about 99% to a sequence selected from the group consisting of SEQ ID NOS: 51-100.

[0078] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising a sequence selected from the group consisting of SEQ ID NO: 64, 65, 66, 87, 98, and 100. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO: 64. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO: 65. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO: 66. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO: 87. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO: 98. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a heavy chain comprising SEQ ID NO: 100.Table 6HeavyVH FcChainSEQ ID SEQ ID Heavy Chain (VH-Fc) Amino Acid Sequence SEQ ID NO: NO:NO:EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGNGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN1 132 51 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN2 132 52 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN3 132 53 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAtorney Docket Number: 92VF-409083-WOEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWV STISGSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 54 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWV SSISGGGDSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGKLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 55 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMTWVRQAPGKGLEWV STISGSGDNTYYADSVKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 56 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLLESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWV SSISGSGDSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 57 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 58 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISSNGSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 59 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLVESGGGLVQPGGSLRLSCAASGFNFSDYYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 60 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAtorney Docket Number: 92VF-409083-WOQVQLVESGGGLVKPGGSLRLSCEASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 61 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMTWVRQAPGKGLEWV STISGSGDNTYYADSVKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 62 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLVESGGGLVQPGGSLRLSCTASGFTLSSYAMSWVRQVPGKGLEWV SAISGGGDNTYYADSVKGRFTISRDTSKNTLYLQMNSLSAEDTAVYYC EKAPYYDILTGYSPVHYWGQGALVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 63 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 64 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFIFSDYYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 65 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGDLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 66 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWI SYISSSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 67 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAtorney Docket Number: 92VF-409083-WOEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWV SAISGSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 68 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISSNGSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 69 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWV STISGSGDNTYYADSVKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 70 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWV SSISGGGDSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGKLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 71 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRVEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 72 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWV STISGSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 73 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFTFRDYYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 74 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAtorney Docket Number: 92VF-409083-WOEVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 75 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWV STISGSGDNTYYADSVKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 76 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 77 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWV SSISGSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 78 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWV SSISGSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 79 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 80 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWV STISGSGDNTYYADSVKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 81 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAtorney Docket Number: 92VF-409083-WOEVQLLESGGGLVQPGGSLRLSCTASGFTLSSYAMSWVRQVPGKGLEWV SAISGGGDNTYYADSVKGRFTISRDTSKNTLYLQMNSLSAEDTAVYYC EKAPYYDILTGYSPVHYWGQGALVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 82 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK QVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 83 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWV STISGSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILSGYSAAAYWGQGNLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 84 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 85 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLLESGGGLVQPGGSLRLSCAASGFTFGSYAMTWVRQAPGKGLEWV SSISGGGDSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYC EKDPYYDILTGYSAAVYWGQGKLVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 86 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 87 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 88 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAtorney Docket Number: 92VF-409083-WOQVQLVESGGGLVQPGGSLRLSCTASGFTLSSYAMSWVRQVPGKGLEWV SAISGGGDNTYYADSVKGRFTISRDTSKNTLFLQMNSLSAEDTAVYYC EKAPYYDILTGYSPVHYWGQGALVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 89 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC VRGYYSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 90 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGWQPGRSLRLSCAASGFTLSSYAMSWVRQVPGKGLEWV SAISGGGDNTYYADSVKGRFTISRDTSKNTLYLQMNSLSAEDTAVYYC EKAPYYDILTGYSPVHYWGQGALVTVSSGGGGSDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE132 91 VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK EVQLLESGGGLVKPGGSLRLSCAASGFTFSDHYMSWIRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC VRGYYSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 92 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTI H YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC VRGYYSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 93 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK QVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWVRQAPGKGLEWV SYISGSGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 94 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFNFSDYYMSWIRQAPGKGLEWV SYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN132 95 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKAttorney Docket Number: 92VF-409083-WOQVQLLESGGGFVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISNNGSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN46 132 96 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGNGDTI Q YAD S VKGRFT I S RDNAKN S L YLQMN S LRAEDTAVYYC VRGYYSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN47 132 97 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTIQYADSVKGRFTISRDNGKNSMYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN48 132 98 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN49 132 99 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK EVQLLESGGGLVKPGGSLRLSCAASGFTFSDNYMSWIRQAPGKGLEWV SYISGSGDTINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC LRGYNSNYLDWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHN50 132 100 AKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0079] It will also be understood by one of ordinary skill in the art that antibodies as disclosed herein may be modified such that they vary in amino acid sequence from the parental sequence from which they were derived. For example, a polypeptide or amino acid sequence derived from a designated protein may be similar, e.g., have a certain percent identity to the starting sequence, e.g., it may be 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the starting sequence.

[0080] Antibodies, variants, or derivatives thereof of the disclosure include derivatives that are modified, i. e. , by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to the epitope. For example, but not by way of limitation, the antibodies can be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemicalAttorney Docket Number: 92VF-409083-WOcleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the antibodies may contain one or more non-classical amino acids.

[0081] The antibodies and antibody fragments described herein may have various uses and applications. In some embodiments, the antibodies and antibody fragments may be used as binding effector molecules to a receptor that is internalized into the early endosome for intracellular sorting. In certain embodiments, the internalizing effector molecule is selected from the group consisting of 5T4, ABCD6, ABCD9, ADAM9, ADGRL3, AGER, ALPP, ANPEP, APLP2, APOA1, APOCI, APOC3, ASGPR, AXL, B7-H4, CD151, CD163, CD163L1, CD166, CD205, CD228, CD276 / B7-H3, CD36, CD40, CD44, CD46, CD5, CD56, CD63, CD68, CD81, CD9, CDH17, CEACAM5, CEACAM6, CLDN18, COLEC12, CRIM1, CXCL16, DAGLB, DLK1, ECE1, ENPP3, EPCAM, FLT4, GAS1, GFRA2, GJA1, GPR56, GRP143, GRP20, HER3, HS6ST1, HS6ST2, 1-Ag7, ITGB1, ITGB6, ITM2B, ITM2C, KAAG1, L1CAM, LAPTM4A, LAPTM4B, LAPTM5, LDLR, LDLRAD3, LGR5, LIMP2, LMBD1, LOX1, LRP1, LRP10, LRP11, LRP12, LRPlb, LRP2, LRP3, LRP4, LRP5, LRP6, LRP8, LRRC15, LY6E, LY6G6G, LY75, M6PR, MARCO, MCOLN1, MELTF, MSLN, MSR1, MST1R, MUC1, MUC16, MUC5A, NEO1, PRLR, RDS, RNF128, RNF43, ROR1, SCAMPI, SCARA3, SCARA5, SEZ6, SLC18B1, SLC34A2, SLC35C2, SLC35F2, SLC39A1, SLC39A6, SLC9B2, SORCS1, SORCS2, SORL1, SORT1, SR-B1, SREC1, SREC2, STAB1, STAB2, STARD3, STEAP1, STn, TfR, TFR2, TGFBRAP1, TGOLN2, TM4SF1, TNFRSF10B, TNFRSF10D, TROP2, TSPAN12, TSPAN18, TSPAN7, and VLDLR.

[0082] In some embodiments, these antibodies and antibody fragments can be paired with an additional functional pairing partner for targeting a unique and specific extracellular target for lysosomal degradation.

[0083] In certain embodiments, the target molecule is a cell surface molecule comprising an allergenbinding protein, a cytokine-binding protein, a cytokine receptor, a wnt-binding protein, a growth factor- binding protein, a growth factor receptor, a G protein-coupled receptor, a lipoprotein- binding protein, a lipoprotein receptor, a hormone-binding protein, a hormone receptor, a membrane channel, a ligand-gated ion channel, a voltage-gated ion channel, and a GPI-linked protein, cell surface receptors, membrane-bound ligands, ion channels, and any other monomeric or multimeric polypeptide component with an extracellular portion that is attached to or associated with a cell membrane.

[0084] In certain embodiments, the cell surface receptors comprise stem cell receptors, immune cell receptors, growth factor receptors, cytokine receptors, hormone receptors, receptor tyrosine kinases, a receptor in the epidermal growth factor receptor (EGFR) family (e.g., HER2 (human epidermal growth factor receptor 2)), a receptor in the fibroblast growth factor receptor (FGFR) family, a receptor in the vascular endothelial growth factor receptor (VEGFR) family, a receptor in the platelet derived growth factor receptor (PDGFR) family, a receptor in the rearranged during transfectionAttorney Docket Number: 92VF-409083-WO(RET) receptor family, a receptor in the Eph receptor family, a receptor in the discoidin domain receptor (DDR) family, and a mucin protein (e.g., MUC1).

[0085] In certain embodiments, the extracellular molecule is selected from a secreted protein that accumulates in disease, allergen, a pathogen, pathogenic molecules, a cholesterol carrier, an infectious disease toxin, an infectious particle, a clotting factor, a chemokine or cytokine, a growth factor, a proteinaceous hormone, a proteinaceous mediator of a mood disorder, a proteinaceous mediator of energy homeostasis, a proteinaceous allergen present in the bloodstream or an antibody against such an allergen, and a proteinaceous toxin.

[0086] In certain embodiments, the extracellular molecule is IgE, C5, a wnt protein, a frizzled protein, a growth factor, a lipoprotein, a hormone, a pathogen or fragment thereof, VEGF, RSV, NGF, angiopoietin-2 (Ang2), myostatin (GDF8), IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, SOST, DKK1, Fel DI, Betvl, CryJi, Candida albicans, S. aureus, LPS, LTA, Protein A, or toxins.

[0087] In some embodiments, the paired bifunctional entity is a bispecific antibody. It will also be understood by one of ordinary skill in the art that antibodies or fragments as disclosed herein may be utilized as building blocks for multi-specific binding entities in which each binding domain is composed of tandem domains comprising n^ 1 of each binding domain, antibody or antibody fragment.

[0088] In some embodiments, the antibodies and antibody fragments described herein may be conjugated to one or more payloads such as therapeutic agents, small molecules, prodrugs, peptides, proteins, oligonucleotides, enzymes, viruses, lipids, biological response modifiers, pharmaceutical agents, cytotoxic agents, or PEG. The antibodies may be conjugated or fused to a payload, which may include detectable labels such as radioactive labels, an immunomodulator, a hormone, an enzyme, an oligonucleotide, a photoactive therapeutic or diagnostic agent, a cytotoxic agent, which may be a drug or a toxin, an ultrasound enhancing agent, a non-radioactive label, a combination thereof and other such agents known in the art. In some embodiments, the payload functions to modulate the transcription of a DNA sequence, to modulate the expression of a protein, or to modulate the activity of a protein. In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a target gene. Examples of oligonucleotides include, but are not limited to, RNAi oligonucleotides (e.g., siRNAs, shRNAs), microRNAs, gapmers, mixmers, phosphorodiamidite morpholinos, peptide nucleic acids, aptamers, and guide nucleic acids (e.g., Cas9 guide RNAs).

[0089] The antibodies can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antigen-binding polypeptide is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.Attorney Docket Number: 92VF-409083-WO

[0090] The antibodies can also be detectably labeled using fluorescence emitting metals such as152EU, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentaacetic acid (DTP A) or ethylenediaminetetraacetic acid (EDTA). Techniques for conjugating various moieties to an antibody are well known, see, e.g., Amon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985); Hellstrom et al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery (2ndEd.), Robinson etal., (eds.), Marcel Dekker, Inc., pp. 623- 53 (1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in Monoclonal Antibodies ‘84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), Academic Press pp. 303-16 (1985), and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. (52:119-58 (1982)).Polynucleotides Encoding the Antibodies and Methods of Preparing the Antibodies

[0091] The present disclosure also provides isolated polynucleotides or nucleic acid molecules encoding the antibodies, variants or derivatives thereof of the disclosure. The polynucleotides of the present disclosure may encode the entire heavy and light chain variable regions of the antigen-binding polypeptides, variants or derivatives thereof on the same polynucleotide molecule or on separate polynucleotide molecules. Additionally, the polynucleotides of the present disclosure may encode portions of the heavy and light chain variable regions of the antigen-binding polypeptides, variants or derivatives thereof on the same polynucleotide molecule or on separate polynucleotide molecules.

[0092] Methods of making antibodies are well known in the art and described herein. In certain embodiments, both the variable and constant regions of the antigen-binding polypeptides of the present disclosure are fully human. Fully human antibodies can be made using techniques described in the art and as described herein. For example, fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Exemplary techniques that can be used to make such antibodies are described in U.S. patents:6,150,584; 6,458,592; 6,420,140 which are incorporated by reference in their entireties.EXAMPLESExample 1: Expression and Purification

[0093] The recombinant plasmids encoding target antibodies were transiently transfected into HEK293-6E cells (National Research Council) using PEI (Polyscience, Catalog # 24885). After transfection, the cells were incubated at 37°C with 5% CO2 and shaking at 120 rpm. The cell culture supernatants containing target antibodies were harvested 6-7 days post transfection by centrifugationAttorney Docket Number: 92VF-409083-WOand filtration. Monoclonal antibodies were purified using Protein A magnetic beads (AmMag Protein A Magnetic Beads, Genscript, Catalog # L00695). In certain circumstances, an additional purification step, size exclusion chromatography (Superdex 200, Cytiva), was completed to remove high molecular weight species before binding properties were measured. The purity of the antibodies was tested by SEC-HPLC (Agilent 1260 Infinity II HPLC with Welch Xtimate SEC-300 Colum, 1 x PBS pH 7.4 as mobile phase) and SDS-PAGE (SurePAGE, Bis-Tris, 10x8, 4-12%, 12 wells, Genscript, Catalog # M00653). The resulting yield and purity of Anti-TfRl HCAb fragments with Fc domain are shown in Table 7.Table 7HCAb fragment Yield (mg / L) % Purity ProA (SEQ ID NO:) (ProA-HPLC) (SEC-HPLC)51 228.3 76.0 52 191.8 93.2 53 193.8 96.4 54 210.0 73.6 55 222.0 73.8 56 253.5 81.0 57 187.5 64.9 58 177.5 91.9 59 217.3 97.5 60 207.3 98.1 61 222.0 98.1 62 224.0 72.8 63 233.0 71.2 64 227.5 95.6 65 173.8 96.8 66 138.8 91.0 67 209.5 96.5 68 209.5 72.0 69 181.3 97.9 70 184.0 77.7 71 230.3 72.8 72 95.8 95.2 73 192.5 72.5 74 139.5 95.3 75 82.3 92.3 76 194.3 73.6 77 160.0 94.5 78 230.3 76.4 79 199.5 75.9 80 97.0 91.7 81 194.0 80.382 212.8 87.9Atorney Docket Number: 92VF-409083-WO83 168.8 95.1 84 143.8 93.1 85 121.0 94.3 86 202.0 75.4 87 200.8 97.1 88 162.0 97.1 89 202.3 79.5 90 157.3 90.1 91 240.5 87.1 92 192.5 92.9 93 247.8 95.5 94 218.5 98.1 95 185.0 97.8 96 193.0 97.3 97 194.3 97.7 98 219.5 97.8 99 134.0 95.8100 157.5 96.8Example 2. Evaluation of Human TfRl Binding by Biolayer Interferometry (BLI)

[0094] HCAb binding to human TfRlwas performed via BLI on a GatorPrime (Gator Bio) using anti -human IgG Fc Gen II (HFCII) probes. Binding measurements were done in 20 mM citric acid / phosphate buffer (pH 7.4), 150 mM NaCl, and 0.05% Tween-20 (Assay Buffer). HFCII probes were equilibrated for 10 minutes with shaking in Assay Buffer and regenerated according to manufacturer guidelines using Regeneration Buffer (Gator Bio) before first use. HCAbs were diluted to 1.Omg / mL and immobilized on the probes (response ~0.5nm). After a baseline step, antibody-loaded probes were dipped into a 1:3 dilution series (top concentration of 365nM) of recombinant human TfRl -His (Aero) for 200 seconds to allow for antigen association and konmeasurement. Probes were dipped back into Assay Buffer for 10 minutes to allow for antigen dissociation and kOff measurement. Binding kinetics were determined using the GatorOne K Analysis software. Binding affinities of Anti-TfRl HCAb fragments with Fc domain to human TfRl as measured by BLI, is shown in Table 8. As shown in Table 8, the antibodies showed KD value of 6.92 x 10'9M or less. Several antibodies showed KD value of less than 1 x 10'12M.Table 8HCAb fragmentKD(M)(SEQ ID NO:)51 6.92E-0952 <1.0E-1253 4.60E-0954 1.54E-0955 <1.0E-1256 <1.0E-12Attomey Docket Number: 92VF-409083-WO57 1.56E-0958 6.97E-1059 2.56E-0960 <1.0E-1261 <1.0E-1262 2.35E-0963 7.63E-1064 <1.0E-1265 <1.0E-1266 5.84E-1067 6.85E-1068 3.34E-1069 8.73E-1070 7.60E-1071 3.23E-1072 1.45E-0973 <1.0E-1274 4.07E-0975 1.53E-0976 <1.0E-1277 1.11E-0978 3.12E-1079 7.60E-1080 <1.0E-1281 <1.0E-1282 <1.0E-1283 <1.0E-1284 8.16E-1085 8.29E-1086 4.05E-0987 <1.0E-1288 <1.0E-1289 5.93E-1090 <1.0E-1291 7.31E-1192 1.01E-0993 3.40E-0994 <1.0E-1295 <1.0E-1296 <1.0E-1297 3.00E-0998 <1.0E-1299 1.64E-09100 3.89E-09Example 3. Evaluation of Human Transferrin Blocking by Flow Cytometry

[0095] To study the activity of human anti-hTFRl HCAb antibodies in blocking the binding of human TF to its receptor human TFR1 in vitro, HEK293T human TFR1 cell was used to perform celllevel human TF / human TFR1 binding and blocking experiments. In brief, anti-TFRl antibodies were serially diluted in PBS. Antibody solution and final concentration 0.1 pg / mL Biotinylated human TF-Attorney Docket Number: 92VF-409083-WOHis protein (Aero, Catalog # TRN-H82E3) solution were incubated with 1x105 cells at 4°C for 1 hour. The cells were washed twice with PBS, and 100 pL of 1:200 diluted florescent labelled Streptavidin (eBioscience™ Streptavidin PE Conjugate, Invitrogen™, Catalog # 12-4317-87) was added into each well. After 30 min incubation at 4°C, cells were washed twice with staining buffer and median fluorescence intensity (MFI) of each sample was collected by flow cytometry. The inhibition rate represented as % blocking is calculated by the following formula: Transferrin Blocking (%) =(MFI antibody - MFI secondary antibody only) / (MFI biotinylated human Transferrin -MFI secondary antibody only)xl00. The calculated transferrin blocking (%) is shown in Table 9. As shown in Table 9, all antibodies showed transferring blocking % of less than 20%, so the antibodies did not substantially inhibit binding of transferrin to TfRl, and did not compete with transferrin. In Table 9, antibodies that did not compete with transferrin and that showed increased binding in the presence of transferrin are listed as having negative percent transferrin blocking.Table 9HCAb fragment (SEQ ID % TransferrinNO:) Blocking51 14.4552 -51.3753 -60.2454 16.6355 16.1056 11.4157 17.7158 -41.5159 -36.8860 -29.3761 -35.7362 5.9063 22.0164 -48.8065 -51.2566 -57.2767 -31.6468 21.1369 -37.6370 9.6371 9.6972 -50.5273 1.6874 -69.8075 -39.9776 5.0477 -56.0778 9.5879 8.4680 -38.1481 6.9682 15.42Attorney Docket Number: 92VF-409083-WO83 -34.8984 -44.4985 -39.4186 19.8187 -44.8888 -83.3689 17.9190 -12.3091 18.4092 -9.3393 -8.5694 -82.0695 -31.9696 -68.5197 -15.3698 -93.6699 -86.42100 -27.31Example 4. Evaluation of Anti-TfRl HCAb Fragments with Fc domain Uptake into Human Cells

[0096] Wild type (WT) 293T cells were cultured in complete medium consisting of DMEM (Gibco) supplemented with 10% FBS and IX Pen / strep and maintained at 37 degrees at 5% CO2 293T cells were seeded in a 96-well plate, 24 hours prior to treatment at a density of 15,000 cells / well. 25nM TfRl antibodies were precomplexed with 75nM to Fabfluor red for 15 minutes at room temperature in complete media. Media was aspirated from cells and antibody. Fabfluor red complex was added to the plate containing cells. Plates were incubated for 48 hours at 37°C in Incucyte live cell imager. An image was acquired every hour at 10X magnification in the red and phase channels. The internalization of antibody measured by acquisition of red fluorescent signal over 48 hours was displayed as area under the curve (AUC) and normalized to IgGl isotype control on each plate. The results are shown in Table 10. In Table 10, antibody fragments with less uptake than the background IgGl isotype control are listed as having negative FabFluor Integrated Intensity.Table 10HCAb fragment FabFluor Integrated Intensity AUCO-48(SEQ ID NO:) (normalized to hlgGl plate control)51 195523352 -16326953 13434954 407256155 654889456 283512857 450412758 274759 183939960 145544461 702133Attorney Docket Number: 92VF-409083-WO62 416564363 672696164 106402065 115672866 152471367 1996868 463583269 -25162670 521893671 716884972 186251573 539429774 38502475 -1330876 540793677 -19863078 527391179 690217080 573981 751666182 561719683 -14523484 11140385 121151286 900264387 77455888 23313889 1034171890 656513791 1335203392 641655393 353627794 -50948995 29397796 -97523697 572685698 217691599 57508100 1219069* * *

[0097] The present disclosure is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the disclosure, and any compositions or methods which are functionally equivalent are within the scope of this disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present disclosure without departing from the spirit or scope of the disclosure. Thus, it is intended that the present disclosure cover the modifications and variations of this disclosure provided they come within the scope of the appended claims and their equivalents.Attorney Docket Number: 92VF-409083-WO

[0098] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Claims

1. Attorney Docket Number: 92VF-409083-WOCLAIMS1. An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof binds to human TfRl and comprises:a heavy chain complementarity determining region (CDRH) 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110;a CDRH2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, and 126; anda CDRH3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 127, 128, 129, 130, and 131.

2. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable region (VH) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50.

3. The antibody or antigen-binding fragment thereof of claim 1 or 2, comprising a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50.

4. The antibody or antigen-binding fragment thereof of claim 1 or 2 comprising a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3-18, 20-24, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3-18, and 20-24.

5. The antibody or antigen-binding fragment thereof of any one of claim 1, 2, and 4, comprising a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3-18, and 20-24.Attorney Docket Number: 92VF-409083-WO6. The antibody or antigen-binding fragment thereof of claim 1, comprising:the CDRH1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 101, 105, and 106;the CDRH2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 114, 115, and 116; andthe CDRH3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 127, 128, 129, 130, and 131.

7. The antibody or antigen-binding fragment thereof of claim 1 or 6, comprising:(a) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 101;the CDRH2 comprising an amino acid sequence of SEQ ID NO: 116; andthe CDRH3 comprising an amino acid sequence of SEQ ID NO: 127;(b) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 105;the CDRH2 comprising an amino acid sequence of SEQ ID NO: 114; andthe CDRH3 comprising an amino acid sequence of SEQ ID NO: 127;(c) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 106;the CDRH2 comprising an amino acid sequence of SEQ ID NO: 115; andthe CDRH3 comprising an amino acid sequence of SEQ ID NO: 127; or(d) the CDRH1 comprising an amino acid sequence of SEQ ID NO: 106;the CDRH2 comprising an amino acid sequence of SEQ ID NO: 114; andthe CDRH3 comprising an amino acid sequence of SEQ ID NO: 127.

8. The antibody or antigen-binding fragment thereof of any one of claim 1, 6, and 7, comprising the VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50, or an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50.Attorney Docket Number: 92VF-409083-WO9. The antibody or antigen-binding fragment thereof of any one of claim 1 and 6-8, comprising the VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50.

10. The antibody or antigen-binding fragment thereof of any preceding claims, further comprising an Fc region.

11. The antibody or antigen-binding fragment thereof of claim 10, wherein the Fc region is derived from human IgGl.

12. The antibody or antigen-binding fragment thereof of claim 10 or 11, wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 132.

13. The antibody or antigen-binding fragment thereof of any one of claims 1-3, comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 51-100.

14. The antibody or antigen-binding fragment thereof of any one of claims 1-3, and 13, comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 64, 65, 66, 87, 98, and 100.

15. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the antibody or antigen-binding fragment thereof is a heavy chain-only antibody (HCAb) or a fragment thereof.

16. A heavy chain-only antibody (HCAb) or antigen-binding fragment thereof, wherein the heavy chain-only antibody binds to human TfRl and comprises a VH domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-50.Attorney Docket Number: 92VF-409083-WO17. The antibody or antigen-binding fragment thereof of claim 16, wherein the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16, 37, 48, and 50.

18. The antibody or antigen-binding fragment thereof of claim 16 or 17, further comprising an Fc region comprising the amino acid sequence of SEQ ID NO: 132.

19. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment thereof binds to the apical domain of human TfRl.

20. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment binds to human TfRl with KD value of 6.97 x 10'9M or less.

21. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment binds to human TfRl with KD value of 1 x IO-10M or less.

22. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment binds to human TfRl with KD value of 1 x 10'11M or less.

23. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment binds to human TfRl with KD value of 1 x IO-12M or less.Attorney Docket Number: 92VF-409083-WO24. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment does not substantially inhibit binding of transferrin to TfRl.

25. The antibody or antigen-binding fragment thereof of any preceding claims, wherein the isolated antibody or antigen-binding fragment inhibits binding of transferrin to TfRl by less than 20%.

26. A composition comprising the antibody or antigen-binding fragment thereof of any preceding claims.

27. A polynucleotide encoding one of the polypeptide chains of the antibody or antigen-binding fragment thereof of any one of claims 1-25.

28. An isolated cell comprising one or more polynucleotide encoding the antibody or fragment thereof of any one of claims 1-25.